Literature DB >> 21453299

Systemic bioavailability of hydrofluoroalkane formulations containing fluticasone propionate and salmeterol.

Peter T Daley-Yates, David A Parkins.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21453299      PMCID： PMC3162666          DOI： 10.1111/j.1365-2125.2011.03978.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  3 in total

Review 1.  Analysis of cascade impactor mass distributions.

Authors:  Craig Dunbar; Jolyon Mitchell
Journal:  J Aerosol Med       Date:  2005

2.  Systemic bioavailability of hydrofluoroalkane (HFA) formulations of fluticasone/salmeterol in healthy volunteers via pMDI alone and spacer.

Authors:  Karine L Clearie; Peter A Williamson; Sriram Vaidyanathan; Jeannine Du Bois; Haylene Nell; Brian J Lipworth
Journal:  Br J Clin Pharmacol       Date:  2010-06       Impact factor: 4.335

3.  Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 microg and fluticasone propionate 250 microg: implications for establishing bioequivalence of inhaled products.

Authors:  Peter T Daley-Yates; David A Parkins; Marian J Thomas; Benjamin Gillett; Karen W House; Hector G Ortega
Journal:  Clin Ther       Date:  2009-02       Impact factor: 3.393
  3 in total
  1 in total

Review 1.  Clinical utility and development of the fluticasone/formoterol combination formulation (Flutiform(®)) for the treatment of asthma.

Authors:  Ricardo Antonio Tan; Jonathan Corren
Journal:  Drug Des Devel Ther       Date:  2014-09-30       Impact factor: 4.162
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.